Polymersome-based protein drug delivery–quo vadis?

MG Gouveia, JP Wesseler, J Ramaekers… - Chemical Society …, 2023 - pubs.rsc.org
Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

AM Didierlaurent, B Laupèze, A Di Pasquale… - Expert review of …, 2017 - Taylor & Francis
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by
enhancing antigen presentation to antigen-specific immune cells with the aim to confer long …

Vaccine adjuvants: from 1920 to 2015 and beyond

A Di Pasquale, S Preiss, F Tavares Da Silva, N Garçon - Vaccines, 2015 - mdpi.com
The concept of stimulating the body's immune response is the basis underlying vaccination.
Vaccines act by initiating the innate immune response and activating antigen presenting …

Current state and challenges in developing oral vaccines

JEV Ramirez, LA Sharpe, NA Peppas - Advanced drug delivery reviews, 2017 - Elsevier
While vaccination remains the most cost effective strategy for disease prevention,
communicable diseases persist as the second leading cause of death worldwide. There is a …

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

P Novak, R Schmidt, E Kontsekova, N Zilka… - The Lancet …, 2017 - thelancet.com
Background Neurofibrillary pathology composed of tau protein is a main correlate of
cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting …

[HTML][HTML] Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies

OS Kumru, SB Joshi, DE Smith, CR Middaugh, T Prusik… - Biologicals, 2014 - Elsevier
Instability of vaccines often emerges as a key challenge during clinical development (lab to
clinic) as well as commercial distribution (factory to patient). To yield stable, efficacious …

Advances in infectious disease vaccine adjuvants

J Fan, S Jin, L Gilmartin, I Toth, WM Hussein… - Vaccines, 2022 - mdpi.com
Vaccines are one of the most significant medical interventions in the fight against infectious
diseases. Since their discovery by Edward Jenner in 1796, vaccines have reduced the …

Protein–excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development

TJ Kamerzell, R Esfandiary, SB Joshi… - Advanced drug delivery …, 2011 - Elsevier
The purpose of this review is to demonstrate the critical importance of understanding protein–
excipient interactions as a key step in the rational design of formulations to stabilize and …

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in …

E Kontsekova, N Zilka, B Kovacech, P Novak… - Alzheimer's research & …, 2014 - Springer
Introduction We have identified structural determinants on tau protein that are essential for
pathological tau–tau interaction in Alzheimer's disease (AD). These regulatory domains …

Drug and vaccine development for the treatment and prevention of urinary tract infections

VP O'brien, TJ Hannan, HV Nielsen… - Urinary Tract Infections …, 2017 - Wiley Online Library
Urinary tract infections (UTI) are one of the most common bacterial infections, with roughly
eleven‐million cases reported in the US each year that cost an estimated $5 billion annually …